Jpmorgan Chase & CO Moon Lake Immunotherapeutics Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.12 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$437 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$153 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$143 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$120 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.9B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...